GlobeNewswire: Ambu A/S Contains the last 10 of 1127 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:14:07ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/09/2826925/0/en/Ambu-A-S-Reporting-of-transactions-made-by-persons-discharging-managerial-responsibilities.html?f=22&fvtc=4&fvtv=8821Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities2024-02-09T15:45:22Z<![CDATA[Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.]]>https://www.globenewswire.com/news-release/2024/02/06/2824350/0/en/GRANT-OF-PERFORMANCE-SHARE-UNITS.html?f=22&fvtc=4&fvtv=8821GRANT OF PERFORMANCE SHARE UNITS2024-02-06T13:41:03Z<![CDATA[Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees.]]>https://www.globenewswire.com/news-release/2024/01/30/2819575/0/en/INTERIM-REPORT-FOR-Q1-2023-24.html?f=22&fvtc=4&fvtv=8821INTERIM REPORT FOR Q1 2023/242024-01-30T06:00:00Z<![CDATA[In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT, combined with pulmonology growing 18%.]]>https://www.globenewswire.com/news-release/2023/11/08/2775798/0/en/ANNUAL-REPORT-2022-23-EARNINGS-RELEASE.html?f=22&fvtc=4&fvtv=8821ANNUAL REPORT 2022/23 (EARNINGS RELEASE)2023-11-08T06:08:07Z<![CDATA[For the full 2022/23 financial year, Ambu reported 7.6% organic revenue growth. This was driven by Endoscope Solutions posting 15% organic growth, the main drivers being urology and ENT growing high double-digits, as well as pulmonology contributing positively, with a strengthened offering. As a result of Ambu’s focused execution, the company delivered an EBIT margin of 6.3%, mainly driven by revenue growth and reduced operational costs in distribution and staff, as well as a positive free cash flow of DKK 192m, corresponding to an increase of DKK 650m, compared to last year.]]>https://www.globenewswire.com/news-release/2023/11/08/2775796/0/en/AMBU-ANNOUNCES-FINANCIAL-OUTLOOK-FOR-THE-2023-24-FINANCIAL-YEAR.html?f=22&fvtc=4&fvtv=8821AMBU ANNOUNCES FINANCIAL OUTLOOK FOR THE 2023/24 FINANCIAL YEAR2023-11-08T06:01:46Z<![CDATA[Today, Ambu announces its financial guidance for the fiscal year 2023/24. Also, today, Ambu will publish its Q4 and full-year earnings release along with its Annual Report, including the company’s Sustainability Report, and its Remuneration Report and Corporate Governance Report for 2022/23.]]>https://www.globenewswire.com/news-release/2023/10/11/2758047/0/en/AMBU-APPOINTS-NEW-CHIEF-FINANCIAL-OFFICER.html?f=22&fvtc=4&fvtv=8821AMBU APPOINTS NEW CHIEF FINANCIAL OFFICER2023-10-11T06:36:18Z<![CDATA[Thomas Frederik Schmidt will step down as CFO of Ambu by 31 December 2023; Henrik Skak Bender named as new CFO, effective 1 January 2024.]]>https://www.globenewswire.com/news-release/2023/10/09/2756574/0/en/AMBU-ANNOUNCES-PRELIMINARY-FINANCIAL-RESULTS-FOR-THE-FISCAL-YEAR-2022-23.html?f=22&fvtc=4&fvtv=8821AMBU ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR THE FISCAL YEAR 2022/232023-10-09T10:59:54Z<![CDATA[Today, Ambu announces its preliminary financial 2022/23 results. For the financial year 2022/23, EBIT before special items totalled DKK 302m, with an EBIT margin before special items of 6.3% (previous outlook: 5 – 6%), mainly driven by scale in OPEX and product mix.]]>https://www.globenewswire.com/news-release/2023/09/29/2751817/0/en/AMBU-FINANCIAL-CALENDAR-FOR-2023-24.html?f=22&fvtc=4&fvtv=8821AMBU FINANCIAL CALENDAR FOR 2023/242023-09-29T08:59:45Z<![CDATA[This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2023/24, as well as the date of Ambu’s Annual General Meeting.]]>https://www.globenewswire.com/news-release/2023/08/31/2734884/0/en/INTERIM-REPORT-FOR-Q3-2022-23.html?f=22&fvtc=4&fvtv=8821INTERIM REPORT FOR Q3 2022/232023-08-31T05:01:00Z<![CDATA[In Q3 2022/23, Ambu delivered 8% organic revenue growth and a 7.6% EBIT margin. This was driven by Endoscopy Solutions growing 23%, due to high double-digit growth within urology and ENT, and pulmonology returning to positive growth year-over-year.]]>https://www.globenewswire.com/news-release/2023/07/28/2713269/0/en/Grant-of-Performance-Share-Units-and-reporting-of-transactions-in-accordance-with-Article-19-of-the-Market-Abuse-Regulation.html?f=22&fvtc=4&fvtv=8821Grant of Performance Share Units and reporting of transactions in accordance with Article 19 of the Market Abuse Regulation2023-07-28T14:46:46Z<![CDATA[Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 198,872 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2022/23 have been granted on 28 July 2023. 55,956 of the PSUs have been granted to the Executive Management and 142,916 of the PSUs have been granted to other key employees.]]>